Report on Cancer Immunotherapy Market & Clinical Pipeline Insight

August 12, 2014 by 2012pharmaceutical

Report on Cancer Immunotherapy Market & Clinical Pipeline Insight

Reporter: Aviva Lev-Ari, PhD, RN

SOURCE

http://www.kuickresearch.com/press-details.php?presstitle=Immunotherapy-To-Transform-Cancer-Drug-Market-Dynamics

Release Date: 6-Aug-2014

Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline

“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:

Cancer Immunotherapy Market Overview
Cancer Immunotherapy Market Dynamics
Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
Cancer Vaccine Clinical Pipeline by Phase & Country
Oncolytic Viruses Clinical Pipeline by Phase & Country
Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
Cancer Cell Therapy Clinical Trial Insight by Phase & Country
Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline

The recent years have witnessed the emergence of cancer immunotherapy, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past 15 years, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. Cancer immunotherapy has been made commercial and the market availability of the agents has enabled the pharma companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s immune system.

With the introduction of Yervoy as one of the agents of cancer immunotherapy, it has been identified that there is a large window of opportunity for treating cancer patients successfully. It has been observed that with the use of Yervoy, in the long-term, a majority of the patients have remained free of relapse of cancer for many years. Thus, this finding has strengthened the understanding that the field of cancer immunotherapy has a disruptive potential in the future years after its complete development.

For Report Sample Visit: Cancer Immunotherapy Market & Clinical Pipeline Insight

Or Contact: avinash@kuickresearch.com

Cancer Immunotherapy Market & Clinical Pipeline Insight

Publish Date:- Jul-2014 No Of Pages (1990)

Electronic Access – Single User License	$3000	Buy Now
CD-ROM Mail Delivery	$3600	Buy Now
Hard Copy Mail Delivery	$4200	Buy Now
Electronic Access – Multi-User License	$6000	Buy Now

1. Introduction to Cancer Immunotherapy (Page 6)

2. Mechanism of Cancer Immunotherapy (Page 11)

2.1 Genetic engineering

2.2 Hybridoma Technology

2.3 Humanization of Monoclonal Antibodies

2.4 Overcoming the HAMA Response via Modern Technology

3. Types of Cancer Immunotherapy (Page 14)

3.1 Monoclonal Antibodies

3.2 Checkpoint Inhibitors

3.3 Vaccination

3.4 Non Specific Immunotherapies

4. Why Need for Cancer Immunotherapy (Page 23)

5. Global Cancer Immunotherapy Market Overview (Page 26)

6. Cancer Immunotherapy Market Dynamics (Page 33)

6.1 Favorable Market Drivers

6.2 Key issues to be Discussed

6.3 Future of Cancer Immunotherapy

7. Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country (Page 41)

7.1 Clinical Pipeline Overview

7.2 Clinical Pipeline Insight: Research till Registration

7.3 Marketed Cancer Monoclonal Antibodies

8. Cancer Vaccine Clinical Pipeline by Phase & Country (Page 1088)

8.1 Clinical Pipeline Overview

8.2 Clinical Pipeline Insight: Research till Registration

8.3 Marketed Cancer Vaccines

9. Oncolytic Viruses Clinical Pipeline by Phase & Country (Page 1640)

9.1 Clinical Pipeline Overview

9.2 Clinical Pipeline insight: Research till Registration

10. Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country (Page 1714)

10.1 Clinical Pipeline Overview

10.2 Clinical Pipeline Insight: Research till Preregistration

10.3 Marketed Cancer Cytokines Threapy

11. Cancer Cell Therapy Clinical Trial Insight by Phase & Country (Page 1844)

11.1 Clinical Pipeline Overview

11.2 Clinical Pipeline Insight: Research till Preregistration

11.3 Marketed Cancer Cell Therapy

12. Competitive Landscape: Business Overview & Product Pipeline (Page 1977)

12.1 Advaxis

12.2 Celldex Therapeutics

12.3 Dendreon Corporation

12.4 Galena Biopharma

12.5 ImmunoCellular Therapeutics

12.6 ImmunoGen

12.7 Inovio Pharmaceuticals

12.8 Merck

12.9 NeoStem Oncology

12.10 NewLink Genetics

12.11 Northwest Biotherapeutics

12.12 Novartis

12.13 Peregrine Pharmaceuticals

12.14 Roche

12.15 Seattle Genetics

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Human Immune System in Health and in Disease | Leave a Comment

Comments RSS

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Report on Cancer Immunotherapy Market & Clinical Pipeline Insight

Report on Cancer Immunotherapy Market & Clinical Pipeline Insight

Cancer Immunotherapy Market & Clinical Pipeline Insight

Like this:

Leave a Reply Cancel reply

Follow Blog via Email

Recent Posts

Archives

Categories

Meta

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Report on Cancer Immunotherapy Market & Clinical Pipeline Insight

Report on Cancer Immunotherapy Market & Clinical Pipeline Insight

Cancer Immunotherapy Market & Clinical Pipeline Insight

Share this:

Like this:

Leave a Reply Cancel reply

Follow Blog via Email

Recent Posts

Archives

Categories

Meta